Health Care Sciences & Services

433.8K Papers

Follow See full results

Article Economics

Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm

Catherine M. Lockhart, Cara L. McDermott, Aaron B. Mendelsohn, James Marshall, Ali McBride, Gary Yee, Minghui Sam Li, Aziza Jamal-Allial, Djeneba Audrey Djibo, Gabriela Vazquez Benitez, Terese A. DeFor, Pamala A. Pawloski

Summary: This study developed an algorithm based on claims data to identify cancer patients and chemotherapy regimens for a comparative effectiveness analysis of G-CSF use. The initial algorithm underestimated the number of patients receiving chemotherapy, but by modifying the criteria, the final algorithm successfully identified 886 patients who received G-CSF.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries

Krithika Rajagopalan, Nazia Rashid, Dilesh Doshi

Summary: Pimavanserin is the only FDA approved atypical antipsychotic for Parkinson's Disease Psychosis, while other off-label antipsychotics like quetiapine are also used. Comparative analysis shows that PIM monotherapy results in lower hospitalizations compared to QUE.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan

Wentao Tang, Keigo Hanada, Yoshiharu Motoo, Hiroyuki Sakamaki, Takaaki Oda, Kazuyuki Furuta, Hikaru Abutani, Satoru Ito, Kiichiro Tsutani

Summary: This study examined the potential impact of comprehensive genomic profiling (CGP) testing before standard of care (SoC) on medical costs and clinical outcomes in untreated patients with advanced or recurrent biliary tract cancer (BTC), non-squamous non-small cell lung cancer (NSQ-NSCLC), or colorectal cancer (CRC) in Japan between 2022 and 2026. The results showed that CGP testing before SoC can increase the detection of druggable alterations and improve treatment rates with matched therapies in these cancer types.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Clinical benefits and economic cost-savings of remote electrical neuromodulation (REN) for migraine prevention

Robert Cowan, Alit Stark-Inbar, Liron Rabany, Dagan Harris, Maya Vizel, Alon Ironi, Julio R. R. Vieira, Michelle Galen, Christina Treppendahl

Summary: The use of the Remote Electrical Neuromodulation (REN) device for migraine prevention has been found to significantly reduce headaches and symptoms, decrease healthcare visits and absenteeism, and result in cost savings. This has important clinical and financial incentives for patients, health insurance systems, and employers.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data

Heidi C. Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrome

Summary: This study evaluates the impact of early initiation of aripiprazole once-monthly (AOM) on healthcare resource utilization, risk of hospitalization, and healthcare costs in patients with schizophrenia. The results indicate that patients who initiate AOM early have lower hospitalization rates and healthcare costs compared to those who initiate it later.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Letter Economics

Re: The budget impact of enzyme replacement therapy in type 1 gaucher disease in the United States

Camille Rochmann, Marie Fournier, Judy Hull, Maria Perichon, Ruth Pulikottil-Jacob

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal

Fabian P. Alvarez, Pierre Chevalier, Matthias Borms, Helene Bricout, Catia Marques, Anu Soininen, Tatu Sainio, Christine Petit, Caroline de Courville

Summary: In order to improve the protection provided by the standard dose influenza quadrivalent vaccine (SDQIV), a high-dose vaccine (HDQIV) has been developed specifically for adults aged 60 and older who are at higher risk of complications. This study aimed to determine the cost-effectiveness of HDQIV compared to SDQIV in three European countries (Belgium, Finland, and Portugal). The results showed that HDQIV resulted in improved health outcomes and was cost-effective in all three countries. Overall, the study highlights the importance of considering HDQIV as a viable option for preventing influenza in high-risk populations.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Healthcare utilization and direct medical costs of Huntington's disease among Medicaid beneficiaries in the United States

Anisha M. Patel, Eunice Chang, Caleb Paydar, Sheila R. Reddy

Summary: This study aimed to provide more recent data on healthcare utilization and costs in Huntington's disease (HD) patients. The results showed that HD patients had higher healthcare utilization and costs compared to non-HD patients, and the costs tended to increase with disease progression.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Increased use of 6-monthly gonadotropin-releasing hormone agonist therapy for prostate cancer: a capacity and cost-minimization analysis for England

Philip Cornford, Caolan Halpin, Jelena Sassmann, Ian Frankcom, Saran Braybrook

Summary: This study provides a solution for the National Health Service (NHS) in England to alleviate pressures by switching from monthly or 3-monthly hormone therapy to 6-monthly therapy. This change can reduce costs and time required for treatment, leading to improved overall efficiency and economic benefits for the system.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1

Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Javier De Castro, Amelia Insa, Alex Martinez, Elena Fernandez, Ivana Sullivan, Andres Flores, Natalia Arrabal, David Carcedo, Alba Manzaneque

Summary: This study evaluated the cost-effectiveness of adjuvant atezolizumab in early-stage NSCLC patients with PD-L1 expression >= 50% and without mutations in EGFR or ALK rearrangements in Spain. The results showed that adjuvant treatment with atezolizumab had better effectiveness in terms of life years and quality-adjusted life years compared to best supportive care, but at a higher cost. Sensitivity analysis showed that adjuvant atezolizumab is cost-effective in the majority of simulations, considering the commonly considered cost-effectiveness threshold.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Review Economics

A systematic review of SF-6D health state valuation studies

Liang Wang, Thomas G. Poder

Summary: This study conducted a systematic review of the methods and strategies used in SF-6D studies to elicit values and model the dimensions. The results showed that the value sets for SF-6D differed between countries, highlighting the need to consider cultural and economic differences when developing value sets for more countries.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans

Kruti Joshi, Dominic Pilon, Aditi Shah, Christopher Holiday, Swapna Karkare, Maryia Zhdanava

Summary: This study aimed to describe the real-world use of esketamine intranasal spray and healthcare outcomes among patients with treatment-resistant depression in the United States. The majority of patients completed the induction phase of esketamine treatment, and most dosing intervals were longer than recommended. Mental health-related inpatient and emergency department costs decreased after esketamine initiation.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

The epidemiology and healthcare costs of community-acquired pneumonia in Ontario, Canada: a population-based cohort study

Ryan O'Reilly, Hong Lu, Jeffrey C. C. Kwong, Allison McGeer, Teresa To, Beate Sander

Summary: The present study aimed to determine the short- and long-term healthcare costs associated with community-acquired pneumonia (CAP) from the healthcare payer perspective in Ontario, Canada. Through a retrospective population-based matched cohort study, it was found that CAP is associated with significantly increased acute and long-term healthcare costs compared to unexposed subjects. This study highlights the burden of CAP in both the inpatient and outpatient setting, and will inform strategic healthcare planning for future interventions and healthcare programs.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis

Elliot B. Tapper, Machaon Bonafede, Jesse Fishman, Stephen Dodge, Keith Miller, Ni Zeng, Dave Lewandowski, Alina Bogdanov

Summary: This study aimed to determine the burden of comorbidities, hospitalization, and healthcare costs among patients with NASH in the US. The results showed that higher FIB-4 scores were associated with increased healthcare costs and risk of hospitalization.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain

Umakanth Vudumula, Mausam Patidar, Kapil Gudala, Elizabeth Karpf, Nicholas Adlard

Summary: This study evaluated the impact of early vs delayed ofatumumab initiation and the long-term clinical, societal, and economic outcomes of ofatumumab vs teriflunomide in RMS patients. The results suggest that early initiation of ofatumumab is an effective and cost-saving strategy for improving outcomes in RMS patients. Furthermore, patients receiving ofatumumab for 10 years are projected to have comparatively better outcomes than those receiving teriflunomide.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States

Oralee J. Varnado, Wenyu Ye, Xiaojuan Mi, Russel Burge, Jerry Hall

Summary: Migraine causes indirect costs due to missed time or reduced productivity at home and work, which can be alleviated by treatment with galcanezumab. This study evaluated the indirect cost savings in patients with episodic or chronic migraine receiving galcanezumab compared to placebo. The results showed significant cost savings in patients with episodic migraine, but not in patients with chronic migraine, suggesting that the disease burden may affect the cost savings.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait

Ahmed Swidan, Gihan Hamdy Elsisi, Mohamed M. M. Ibrahim, Mohammad Aljazzar, Hossameldin Tawfik Sallam

Summary: A cost-effectiveness study was conducted to evaluate the use of dapagliflozin as an add-on therapy for CKD patients with or without type-2 diabetes. The results showed that dapagliflozin + ramipril was both more cost-effective and improved quality of life compared to ramipril alone. This study only focused on the DAPA-CKD cohort.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Real-world clinical management of individuals with Rett syndrome: a physician survey

Damian M. May, Jeffrey L. Neul, Ambika Satija, Wendy Y. Cheng, Neema Lema, Andra Boca, Patrick Lefebvre, Jesus Eric Pina-Garza

Summary: This study examines the decision-making and management strategies of physicians in diagnosing and treating patients with Rett syndrome (RTT) in the US. The findings indicate that most physicians use symptom evaluation and genetic testing for RTT diagnosis, with the goal of improving quality of life for patients and caregivers. Clinical practice guidelines are commonly used to monitor progress, but there is an unmet need for novel therapies that target multiple symptoms associated with RTT.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore

Junxing Chay, Joshua Yi Min Tung, Rebecca Jade Su, Edwin Jonathan Aslim, Callix Wong, Georgia Swan, Wei Jin Chua, Henry Sun Sien Ho, Eric Andrew Finkelstein

Summary: This study evaluated the cost-effectiveness of minimally invasive surgical therapies for moderate-to-severe BPH patients in Singapore, finding that WVTT as a first-line treatment is cost-effective for both moderate and severe patients, while PUL is not cost-effective. TURP is cost-effective as a first-line treatment for severe patients only.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Article Economics

Healthcare costs among patients with newly diagnosed helicobacter pylori infection in the United States: a linked claims-EHR study

Shailja Shah, Katherine Cappell, Robert Sedgley, Corey Pelletier, Rinu Jacob, Machaon Bonafede, Rena Yadlapati

Summary: This study aimed to characterize the cost drivers of patients with Helicobacter pylori (HP) and estimate the cost savings associated with successful eradication compared to failed eradication. The results showed that the healthcare costs of HP patients are influenced by comorbidities and there are significant cost savings for patients with successful HP eradication in specific HP-related conditions.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

«
1
2
3
4
5
»

See full results

Related Categories

Anesthesiology (212.5K) Audiology & Speech-Language Pathology (1.7K) Clinical Neurology (1.3M) Critical Care Medicine (338.4K) Dentistry, Oral Surgery & Medicine (340.8K) Dermatology (413.6K) Emergency Medicine (142.9K) Endocrinology & Metabolism (751.7K) Gastroenterology & Hepatology (856.4K) Geriatrics & Gerontology (226.3K) Gerontology (158.2K) Hematology (653.3K) Immunology (896.7K) Infectious Diseases (453.2K) Integrative & Complementary Medicine (99.8K) Medical Ethics (26.6K) Medical Informatics (100.5K) Medical Laboratory Technology (108K) Medicine, General & Internal (1.3M) Medicine, Legal (48.4K) Medicine, Research & Experimental (710K) Nursing (297.8K) Obstetrics & Gynecology (559.8K) Oncology (1.8M) Ophthalmology (452.2K) Orthopedics (359.5K) Otorhinolaryngology (166K) Pediatrics (655.3K) Peripheral Vascular Disease (595.7K) Pharmacology & Pharmacy (1.3M) Primary Health Care (59.2K) Psychiatry (755.1K) Radiology, Nuclear Medicine & Medical Imaging (799.4K) Rehabilitation (249.2K) Rheumatology (300.3K) Surgery (1.3M) Toxicology (333.1K) Transplantation (309.7K) Tropical Medicine (112.2K) Urology & Nephrology (567K) Veterinary Sciences (455.3K)

© Peeref 2019-2024. All rights reserved.